Zenas BioPharma's partner, InnoCare Pharma, reports success achieving primary endpoint in Phase 2b study of Orelabrutinib for systemic lupus erythematosus (SLE), the first BTK inhibitor to show clinical activity in a Phase 2 trial.
In a recent Phase 2 clinical trial for systemic lupus erythematosus (SLE), Orelabrutinib has made history as the inaugural BTK inhibitor to showcase substantial clinical efficacy. This groundbreaking development marks a significant milestone in the treatment of SLE, signifying a promising advancement in combating the disease. This advancement paves the way for further exploration and potential breakthroughs in SLE treatment.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments